Market Access
Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
French Pharma's Forecasted Market Dip
March 14 by Pharma IQExperts have forecasted that the French pharmaceutical market is heading for a period of stagnation, with the market value set to shrink by $1billion over the next four years.Research from consulting...
Serialization and Data Management: Data-On and Data-Out Considerations
March 08 by Pharma IQThe live webinar, hosted by industry experts Thierry Protas (Videojet) and Luc Vallancourt (Optel Vision), is the second and final webinar about data management requirements deriving from serializatio...
Patient Centricity: Why customer experience strategies should still be a priority
February 07 by Pharmaceuticals & Biotechnology EditorWhen it comes to manoeuvrability and nimble response, large companies have more in common with ocean liners than speedboats. Policies are agreed, marketing strategies planned, and future developments...
Novartis CEO talks Drug Prices, Donald Trump and the Future of Pharma Innovation
February 06 by Pharmaceuticals & Biotechnology EditorFollowing are excerpts from a CNBC interview with Joseph Jimenez, CEO of Novartis, from the World Economic Forum 2017 with Carolin Roth.CR: Well, it's certainly a big worry, one healthcare official to...
Pharma and Biotech Market Access Trends: A Look Back at 2016
January 13 by Dr Steven BradshawThe increasing developmental costs, shifting influences between stakeholders, and growing pharmaceutical competition are just some of the factors that are reshaping pharma’s market access schemes. Wit...
Biosimilars Grow From Strength To Strength
January 13 by Pharma IQSteven Bradshaw noted that with several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especiall...
Your 5 Steps To Successfully Enabling Customer Teams
January 05 by Pharmaceuticals & Biotechnology EditorMany life sciences companies are guilty of overlooking the impact of impersonal one-size-fits all email campaigns. Open rates are typically very low for mass emailing campaigns, the average click-thro...
Q4 Pharma & Biotech News: The Highlights
December 20 by Pharma IQThe last quarter of 2016 was certainly not short of activity with a £84 million pharma fine issued in regards to drug pricings, an investigation into a suspected supply chain breach and numerous thera...
Popularity Of Cell Therapy Technology Drives The Regenerative Medicine Market
November 01 by Allied Market ResearchRegenerative medicine is one of the fastest growing industries with huge market potential, it handles the treatment of chronic diseases which remained incurable previously. Cell therapy using live cel...
The Future of US Pharma and Healthcare: Two Very Different Game-plans
November 01 by Pharma IQThe brawl up to the US election has been almost impossible to miss. Amidst watching Trump and Hillary lock-horns, Pharma-IQ examines one of the most important battlegrounds discussed - the future of U...
What Are the Next Game Changing Drugs in Cancer Therapy?
October 25 by Regina AuImmuno-oncology (IO) is the buzz word today and it has everyone doing IO research. Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate w...
What’s in the Pipeline for Pharma?
October 25 by Pharma IQPharma power play hinges mostly on the initial R&D race to market dominance. Research innovation and investment has enticing potential. The Pharmaceutical industry pipeline was noted to have...